
Annual report 2025
added 02-24-2026
PerkinElmer Net Debt 2011-2026 | PKI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt PerkinElmer
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.3 B | 1.99 B | 2.99 B | 1.21 B | - | 1.88 B | 1.73 B | 687 M | 775 M | - | 878 M | 762 M | 803 M | 6.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.99 B | 6.2 M | 1.33 B |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Burning Rock Biotech Limited
BNR
|
-76 M | $ 16.25 | 0.06 % | $ 171 M | ||
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
CareDx, Inc
CDNA
|
-39.2 M | $ 20.65 | -0.75 % | $ 1.1 B | ||
|
Co-Diagnostics
CODX
|
-10.6 M | $ 1.65 | 7.84 % | $ 2.19 M | ||
|
Agilent Technologies
A
|
1.24 B | $ 113.95 | 2.38 % | $ 34.6 B | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 15.07 | 1.82 % | $ 456 M | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 24.54 | 1.24 % | $ 682 M | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 115.88 | -0.25 % | $ 9.56 B | ||
|
Illumina
ILMN
|
-494 M | $ 125.86 | 4.56 % | $ 20 B | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 164.61 | 0.47 % | $ 8.16 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | ||
|
Guardant Health
GH
|
1.15 B | $ 84.55 | 1.37 % | $ 10.6 B | ||
|
Lantheus Holdings
LNTH
|
213 M | $ 81.81 | 0.79 % | $ 5.52 B | ||
|
Medpace Holdings
MEDP
|
-360 M | $ 416.27 | 0.65 % | $ 12 B | ||
|
NeoGenomics
NEO
|
187 M | $ 9.11 | 1.62 % | $ 1.17 B | ||
|
National Research Corporation
NRC
|
71.3 M | $ 16.4 | -0.85 % | $ 367 M | ||
|
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 26.22 | 2.5 % | $ 20 B | ||
|
Personalis
PSNL
|
-48.8 M | $ 5.16 | 2.28 % | $ 306 M | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
Senseonics Holdings
SENS
|
-4.15 M | $ 6.24 | -2.88 % | $ 260 M | ||
|
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.99 | 2.9 % | $ 8.8 M | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
-1.94 M | $ 2.16 | - | $ 4.96 M | ||
|
Thermo Fisher Scientific
TMO
|
29.6 B | $ 475.17 | 1.91 % | $ 179 B | ||
|
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 264.03 | 2.68 % | $ 22 B | ||
|
Trinity Biotech plc
TRIB
|
55.4 M | $ 0.62 | 3.33 % | $ 61.9 M | ||
|
Twist Bioscience Corporation
TWST
|
-107 M | $ 58.32 | 2.86 % | $ 3.49 B | ||
|
Celcuity
CELC
|
-28.1 M | $ 119.44 | 0.37 % | $ 5.58 B | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
751 M | $ 9.28 | 2.94 % | $ 2.01 B | ||
|
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | ||
|
Myriad Genetics
MYGN
|
115 M | $ 4.75 | 1.39 % | $ 440 M | ||
|
OpGen
OPGN
|
711 K | - | -16.95 % | $ 1.54 M | ||
|
Natera
NTRA
|
-177 M | $ 200.62 | 3.01 % | $ 19.7 B | ||
|
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 195.73 | 3.36 % | $ 21.7 B |